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Abstract 1 
Aim 2 
The aim of this feasibility study was to investigate the potential role of a novel 3 
neuromuscular electrical stimulation (NMES) device in preventing the formation of 4 
oedema following total hip replacement (THR). 5 
Methods 6 
Successive primary THR patients were recruited into a randomised controlled trial. 7 
Participants were randomised to wear either the NMES device or compression 8 
stockings continually from post-surgery until discharge.  9 
The main outcome measure was presence of lower limb oedema, assessed by 10 
taking measurements of the circumference of the ankle, knee and thigh on the 11 
operated leg and non-operated leg, pre-operatively, post-operatively, at two days 12 
post-operatively and every day until discharge. Secondary objectives were to 13 
compare adverse events, the presence of asymptomatic and symptomatic deep vein 14 
thrombosis (DVT) and device tolerability between groups. 15 
Results 16 
Data from 40 participants were analysed (NMES (n = 20), compression stockings (n 17 
=20)). The NMES group had significantly less oedema and the device was found to 18 
be tolerable and safe. 19 
Conclusion 20 
The results of this study suggest that the NMES is a safe and well tolerated 21 
alternative to compression stockings, which should be considered by clinicians 22 
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seeking the additional benefit of reducing post-operative oedema. In addition the 23 
NMES device should be considered as part of a DVT prophylaxis. 24 
 25 
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INTRODUCTION 42 
Total hip replacement (THR) is a common and successful surgical solution for the 43 
treatment of osteoarthritis of the hip. The procedure has demonstrated positive 44 
results for patients and the development of surgical techniques, pain management 45 
strategies and enhanced recovery after surgery (ERAS) pathways have improved 46 
outcomes further (Ibrahim et al. 2013). Length of stay has reduced (den Hartog et al. 47 
2013) and return to function has been accelerated with no increase to post-operative 48 
complications or re-admission rates (Husted et al. 2008). In addition, outpatient THR 49 
has been considered feasible in selected (den Hartog et al. 2015) and unselected 50 
patients (Gromov et al. 2017), 51 
However, some issues still remain for patients post-surgery. Husted et al. (2011) 52 
found the main clinical reasons for delayed discharge following THR to be pain, 53 
dizziness and general weakness. Decreased muscle function or weakness 54 
immediately post-op is unlikely to be due to atrophy alone, and the formation of 55 
oedema post-operatively is widely accepted to lead to pain and to exacerbate loss of 56 
muscle function. Clinically, oedema is described as an abnormal build-up of 57 
interstitial fluid in the body that is enough to produce palpable swelling (Kerchner et 58 
al. 2008). In addition to surgical trauma, decreased mobility immediately post-59 
operatively can lead to a reduction in venous return, preventing the movement of 60 
fluid from tissues back into blood vessels (Kerchner et al. 2008).  This creates an 61 
imbalance between capillary filtration and lymph drainage, leading to swelling.  62 
Currently, there is limited evidence that describes the effect of oedema on recovery, 63 
or what percentage of patients develop lower-limb oedema following THR.  64 
Traditional treatment methods for oedema following total knee replacement (TKR) 65 
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may include cooling or cryotherapy, early ambulation, elevation of limbs, 66 
compression stockings and massage to help stimulate the release of excessive 67 
fluids.  68 
An alternative treatment method is neuromuscular electrical stimulation (NMES), 69 
which stimulates nerves to activate muscle, and has been shown to enhance venous 70 
blood flow and reduce oedema in non-hip replacement populations (Doran & White 71 
1967; Dejode et al. 1973, Faghri et al. 1997, Broderick et al. 2010, Tucker et al. 72 
2010). However, the clinical application of NMES for post-surgical oedema 73 
prevention has been limited until now due to concerns over perceived discomfort and 74 
the impractical design of devices (Broderick et al. 2011). A number of studies have 75 
demonstrated that NMES significantly improves blood flow in the deep veins, (Faghri 76 
et al. 1997, Broderick et al. 2010, Tucker et al. 2010, Browse & Negus, 1970, Dejode 77 
et al. 1973) and the NMES device has been found to increase blood flow in the deep 78 
veins of the calf (Griffin et al. 2016). Recent developments in the design of NMES 79 
devices have significantly increased patient comfort and tolerance of NMES by 80 
allowing effective stimulation with lower current density and pulse duration (Broderick 81 
et al. 2011).  These improvements in comfort have been further developed by 82 
utilising indolent nerve stimulation in place of direct muscle stimulation (Browse and 83 
Negus 1970).  84 
 85 
 86 
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The primary objective of this study was to evaluate whether an NMES device is more 88 
efficient than compression stockings (Thromboembolic deterrent stockings (TEDS)) 89 
in preventing the formation of oedema following THR surgery. Compression 90 
stockings were chosen as the comparator as they are routinely used in the study site 91 
for the prevention of lower limb oedema and DVT. Secondary objectives were to 92 
compare the formation of asymptomatic and symptomatic DVT, to compare device 93 
acceptability, tolerability and compliance, and to compare device safety by 94 
monitoring for adverse events. 95 
METHODS 96 
This was a randomised open label study comparing NMES and compression 97 
stockings with full ethical approval granted by the National Research Ethics Service 98 
(NRES) (REC reference 13/LO/0059, Protocol number FKD-TEDS-001, IRAS project 99 
ID 117650). The study was conducted in accordance with the principles of the 100 
Declaration of Helsinki (Ethical Principles for Medical Research Involving Human 101 
Subjects) and in compliance with European Standard ISO 14155:2011 Clinical 102 
Investigations of Medical Devices for Human Subjects – Good Clinical Practice. It 103 
was registered on ClinicalTrials.gov (Identifier: NCT01935414). The study is reported 104 
according to CONSORT guidelines for reporting randomised controlled trials 105 
(CONSORT, 2017). 106 
Consecutive primary THR operations performed by a single surgeon at a private 107 
hospital were screened for eligibility in accordance with the inclusion and exclusion 108 
criteria detailed in Table 1. Recruitment continued until 40 patients had completed 109 
the trial. Eligible patients who consented to take part in the study were randomised 110 
by a clinical researcher with a 1:1 allocation via a sealed envelope prepared by an 111 
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independent Clinical Research Organisation. All participants followed the standard 112 
care pathway for hip replacement and received the standard care for oedema 113 
prevention before surgery, during surgery and on discharge. The only difference in 114 
treatment between the two groups was that from post-surgery until discharge the 115 
participants were randomised to receive either the NMES device or compression 116 
stockings. 117 
The geko™ NMES device was used for the study, which is small disposable and 118 
internally powered and can be applied externally to the leg. The device is 119 
manufactured by Firstkind Ltd., High Wycombe, United Kingdom. It is self-adhesive 120 
and applied to the outer/posterior aspect of the knee. This positioning enables 121 
integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally 122 
termed the common peroneal) which branches from the sciatic nerve These nerves 123 
control the contraction of several muscles in the lower leg. The stimulation of these 124 
nerves by the geko™ device causes the muscles to contract isometrically and will 125 
not affect normal movement of the limb nor mobility of the patient. Contraction of the 126 
lower leg muscles increases blood flow from the lower limbs back to the heart thus 127 
increasing venous return, local blood circulation and help prevent venous thrombosis 128 
(Tucker et al. 2010). Saphena® anti-embolism compression stockings fitted in 129 
accordance to manufacturer instructions were used for the study, with a pressure of 130 
18 mmHg =/-20% administered to the ankle, 14mmHg +/- 20% administered to the 131 
calf and 9mmHg +/- 20% to the thigh. Both devices were worn continually from post-132 
surgery until discharge. In accordance with the manufacturer’s instructions for use, 133 
the NMES device was changed each day.  134 
 135 
 136 
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Table 1 – Details of inclusion and exclusion criteria 137 
Inclusion Criteria 
 Aged 18 years of age and over 
 Free of significant abnormal findings as determined by medical history.  
 Has not used any medications (prescribed or over-the-counter including herbal 
remedies) judged to be significant by the Principal Investigator during the ten (10) 
days preceding enrolment. 
 Able to understand the Patient Information Sheet and willing to sign the written 
Informed Consent Form. 
 Able and willing to follow the protocol requirements. 
Exclusion Criteria 
 Are requiring hip revision surgery 
 History or signs of previous deep or superficial vein thrombosis/pulmonary embolism. 
 Evidence of asymptomatic DVT by Duplex Ultrasound 
 Peripheral arterial disease (ABPI < 0.8), varicose veins or lower limb ulceration or 
ischemia. 
 Significant varicose veins, phlebitis or lower limb ulceration or ischemia. CEAP Grade 
4-6. See Appendix  2 
 Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or 
knee replacement). 
 Recent trauma to lower limb. 
 Chronic Obesity (BMI Index >40kg/m2). 
 Pregnancy. 
 Significant history of following diseases 
 Cardiovascular: Recent MI (< 6 months) 
 Percutaneous Coronary Intervention (PCI) with stent (< 3 months for Bare Metal 
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Stent (BMS) and < 12 months for Drug Eluding Stent (DES) 
 Moderate to severe CCF, uncontrolled AF 
 Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies 
 Significant dermatological conditions affecting lower limbs resulting in broken or 
inflamed skin particularly at the site where the device is to be fitted. 
 Clinically significant haematological conditions i.e. coagulation disorders, sickle cell 
disease 
 Psychiatric disorders 
• On LMWH/Heparin (Prophylactic/therapeutic doses) or Warfarin or 
warfarin stopped recently and replaced by LMWH/ Heparin 
• Long term steroid with dermatological changes 
• A pulse rate of less than 40 beats/minute 
• A sitting systolic blood pressure >180 and <100 mmHg and/or a sitting 
diastolic pressure of >100 mmHg. 
• Any significant illness during the four (4) weeks preceding the hip 
replacement surgery. 
 Participation in any clinical study during the eight (8) weeks preceding the screening 
period 
 138 
 139 
 140 
 141 
 142 
 143 
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Data collection  144 
Data were collected prior to surgery, immediately following surgery, on each post-145 
operative day until discharge, and at 6 weeks following surgery. At each time point 146 
adverse events and device deficiencies were monitored.  147 
Oedema was examined by taking measures of the circumference of the ankle, knee 148 
and thigh on the operated leg and non-operated leg, in the supine position, pre-149 
operatively, post-operatively (prior to fitting of either the NMES or compression 150 
stocking devices), at two days post-operatively and every day until discharge 151 
(typically day four in this study population). The position the measurement was taken 152 
was marked with an indelible marker to ensure that measurements were always 153 
recorded on the same part of the ankle/leg, and the same staff member completed 154 
all measurements. 155 
In addition to oedema evaluation, Duplex Ultrasound was used to assess the 156 
presence or absence of asymptomatic DVT in order to ensure the use of NMES over 157 
compression stocking did not increase DVT risk. All scans were completed by a 158 
consultant radiologist who examined the common femoral vein, superficial femoral 159 
vein, popliteal vein, gastrocnemius veins, soleal veins, posterior tibial veins and 160 
peroneal veins for patency, compressibility and the presence or absence of flow.  161 
Evaluation of the acceptance and tolerability of both compression stockings and the 162 
NMES device was completed by the administration of a Likert Scale questionnaire 163 
designed to assess the level of pain/discomfort felt by the patient on a scale of 1-5.  164 
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Statistical Methodology 165 
 166 
This feasibility study was deemed a necessary first step for the calculation of a 167 
suitable sample size for a future comprehensive study due to the shortage of existing 168 
suitable data for effect size. Incidence rates for oedema vary widely between patient 169 
groups and clinical settings, and the effect size for the NMES device for reducing the 170 
incidence of oedema was as yet unknown. .  171 
  172 
For oedema data, graphs were plotted of circumference versus time and the 173 
gradients compared using a t-test. The frequency of asymptomatic DVT was 174 
recorded for each group at 0hrs (baseline scan) 48hrs post-operatively, discharge 175 
and Week 6. Rates of DVT (asymptomatic or symptomatic) were compared at each 176 
time-point, as well as the differences between time-points. Tolerability data for each 177 
intervention was collected on discharge, and measured using a Likert 1-5 scale. 178 
Interventions were subsequently compared with Mann-Whitney U-test. Additionally, 179 
safety was assessed for each intervention by the recording of adverse events. 180 
Additional data collected such as basic demographic information were checked by 181 
student’s t-test to determine any differences between groups. 182 
 183 
 184 
 185 
 186 
 187 
 188 
 189 
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RESULTS 190 
Successive patients were recruited between 28/08/13 and 09/07/14 until 40 patients 191 
had completed the trial, and follow up of the last patient was completed on 11/08/14. 192 
Forty-one patients scheduled for elective total hip replacement were enrolled into the 193 
study; one subject (021) was withdrawn due to withdrawal of consent as a result of 194 
an adverse event (See Figure 1). In general both study groups were well matched. A 195 
greater proportion of males were in the compression stockings group. The side 196 
operated on was more evenly distributed in the compression stockings population, 197 
whilst the right side received surgery in 70% of the NMES participants (See Table 2). 198 
Table 2 – Baseline demographic and clinical characteristics 199 
 NMES 
Mean ± 95% CI 
Compression 
Stockings 
Mean ± 95% CI 
T-test or *Fishers 
exact p value 
Age (years) 67.2 ± 9.2 67.8 ± 11.9 0.87 
Sex 14 Female/6 Male 5 Female/15 Male *0.01 
BMI (kg/m2) 27.2 ± 4.3 26.5 ± 2.7 0.56 
Treated leg 6 left, 14 right 8 left, 12 right *0.74 
 200 
 201 
 202 
 203 
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Figure 1 - Participant flow diagram 204 
Successive patients undergoing primary THR at the hospital were recruited between 205 
28/08/13 and 09/07/2014 until 40 patients had completed the trial. Follow up of the 206 
last patient was completed on 11/08/14. 207 
 208 
 209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
Assessed for eligibility (n=64) 
Excluded (n=23) 
   Not meeting inclusion criteria (n=14) 
   Declined to participate (n=3) 
   Radiologist and/or ultrasound suite 
unavailable for all required scans (n=6) 
Analysed (n=20 ) 
 Excluded from analysis (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=1) *see notes 
Allocated to standard care (Compression 
stockings) (n=21) 
 Received allocated intervention (n=21) 
 Did not receive allocated intervention (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (give reasons) (n=0) 
Allocated to intervention group (NMES) (n=20) 
 Received allocated intervention (n=20) 
 Did not receive allocated intervention (n=0) 
Analysed (n=20) 
 Excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomised (n=41) 
Enrolment 
Notes - Subject 021 experienced a “clunking sound” from the operated hip 2 days following the index surgery. An x-ray was performed but 
was inconclusive, so the subject underwent an exploratory operation. There were no abnormal findings during the procedure, but the 
operating surgeon (Chief investigator) changed the head of the prosthesis. There was no relation between the SAE and the study device. The 
investigator made the decision to withdraw this subject from the study prior to discharge 
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Oedema 223 
There were no significant differences seen between the pre-operative swelling 224 
measured before the applications of the NMES device or compression stockings at 225 
the ankle (P=0.3), knee (P=0.12) or thigh (P=0.73) in the operated leg. Furthermore 226 
there were no significant differences seen between the post-operative swelling 227 
measured before the applications of the NMES device or compression stockings, at 228 
the ankle (P=0.5), knee (P=0.11) or thigh (P=0.44) in the non-operated leg. 229 
 230 
Figure 2 shows the mean ankle circumference during the post-op period to discharge 231 
relative to pre-op value for the NMES and compression stockings groups. Both 232 
groups exhibited an increase in this parameter, relating to ankle swelling during the 233 
post-op period, after application of the device.  The compression stocking group 234 
ankle circumference increased by 0.48 cm ± 0.2 cm between pre-operative and post-235 
operative measurements, the circumference peaked at day 3 (1 cm ± 0.4 cm) before 236 
dropping to 0.8 cm ± 0.3 cm on the day of discharge. The NMES group also saw an 237 
increase between the pre-operative measurements of ankle circumference and the 238 
post-operative measure prior to the device being fitted (0.3 cm ± 0.1 cm). The NMES 239 
group ankle circumference peaked on the day of discharge at 0.4cm±0.1. The 240 
compression stockings group ankle circumference increased more than the NMES 241 
group though this did not reach significance (p=0.27). 242 
 243 
 244 
 245 
 246 
 247 
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Figure 2 - Ankle circumference in the operated leg 248 
 249 
 250 
Similar results were seen for knee circumference (Figure 3). Both groups show an 251 
increase between pre-operative and post-operative measures before device fitting 252 
(NMES 0.8 cm ± 0.1 cm, compression stockings 1.1cm±0.3)  which continued 253 
through to discharge (NMES 1.3 cm ± 0.2 cm, compression stockings 2.4 cm ± 0.5 254 
cm), but in this case, the increase for the NMES group was significantly smaller than 255 
for the compression stockings group (p=0.02). 256 
 257 
 258 
 259 
 260 
 261 
 262 
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Figure 3 - Knee circumference in the operated leg 263 
 264 
 265 
Similar results were seen for the thigh measurements as shown in Figure 4. Both 266 
NMES and compression stockings groups displayed significant increases in thigh 267 
circumference between pre-operative and post-operative measures prior to fitting the 268 
devices (0.9 cm ± 0.2 cm [p=0.004] and 1.2 cm ± 0.4 cm [p=0.002]). The 269 
circumference was highest in both NMES and compression stockings groups on the 270 
day of discharge (1.5 cm ± 0.3 cm and 2.9 ± 0.6 cm respectively. A significantly 271 
smaller increase in thigh diameter pre-op to discharge for the NMES group (1.5 cm ± 272 
0.3 cm) as compared to the compression stockings group (2.9 cm ± 0.6 cm [p=0.02]) 273 
was observed. 274 
 275 
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Figure 4 - Thigh circumference in the operated leg 276 
 277 
 278 
The treatment devices were worn on both legs by all study subjects.  In the non-279 
operated leg, no significant changes were seen in ankle circumference from 280 
immediate post-op to discharge for either group. 281 
 282 
At the knee, the NMES group showed a non-significant decrease (p=0.19) in non-283 
operated knee circumference immediately post-op (0.33 cm ± 0.1 cm) to discharge 284 
(0.25 cm ± 0.1 cm), while the compression stockings group showed a non-significant 285 
increase (0.23 cm ± 0.2 cm immediately post-op to 0.43 cm ± 0.2 cm [p=0.057]). The 286 
difference between the NMES and compression stockings groups on this parameter 287 
was significant (p=0.016) at discharge. 288 
 289 
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Similarly, at the thigh, the NMES group showed a non-significant decrease (p=0.095) 290 
in thigh circumference of the non-operated leg (post-operative 0.55 cm ± 0.2 cm to 291 
0.1 cm ± 0.3 cm on the day of discharge).  However, the compression stockings 292 
group showed a significant (p=0.021) increase in thigh circumference of the non-293 
operated leg after application post-op (0.38 cm ± 0.3 cm) to discharge (0.75 cm ± 0.3 294 
cm). The difference between the NMES and compression stockings groups was 295 
highly significant (p=0.006) at discharge. 296 
 297 
Incidence of symptomatic or asymptomatic DVT 298 
There were no symptomatic or asymptomatic DVTs observed via ultrasound 299 
occurring at any time point up until 6 weeks in either the NMES or compression 300 
stockings groups. There were no VTE, PE, stroke or deaths recorded during the 301 
study in either NMES or compression stockings treatment groups. 302 
 303 
Patient rated outcome measures 304 
 305 
Participants were asked at the end of their hospital stay the following question 306 
“When compared to a blood pressure cuff inflated around your upper arm, how does 307 
the device/stocking feel?” in order to gain an understanding as to their tolerance of 308 
the device. Over 80% of all participants i.e those randomised to NMES and 309 
compression stockings reported minimal or no sensation from their devices. There 310 
were n=5 compression stockings participants who reported either mild or severe 311 
discomfort caused by their devices, compared with only n=2 NMES participants 312 
reporting the same, this however did not reach significance (Fisher Exact Test, 313 
P=0.28), see table 3 below 314 
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Table 3 - Patient reported comfort 315 
How does the device 
feel 
Group 
 
 NMES Compression 
stockings 
Total 
1= No sensation 1 (2.5%) 4 (10%) 5 (12.5%) 
2= Minimal sensations 16 (40%) 12 (30%) 28 (70%) 
3= Mild discomfort 2 (5%) 4 (10%) 6 (15%) 
4= Moderate 
discomfort 
0 (0%0 0 (0%) 0 (0%) 
5= Severe discomfort 0 (0%) 1 (2.5%) 1 (2.5%) 
 316 
Adverse events 317 
 318 
A total of 19 adverse events (AEs) were reported during the study. The majority of 319 
these were post-operative pain (n=12, 63.2%).  None had causality related to the 320 
device. From these 19 adverse events, 4 were classified as serious adverse events 321 
(SAEs). None of the SAEs were considered Unanticipated Serious Adverse Device 322 
Effects (USADEs). No device deficiencies were reported throughout the duration of 323 
the study. 324 
 325 
 326 
 327 
 328 
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DISCUSSION 329 
This feasibility study was set up to provide data to adequately power a larger, multi-330 
centre study. As such, the statistical powering and sample size of 40 participants 331 
was not designed to identify differences in oedema or DVT incidence between the 332 
interventions. Whilst the sample size is small, the fact that this was a single surgeon 333 
series, within the same hospital means that a high degree of pathway and treatment 334 
standardisation was possible. This is an important factor when assessing outcomes 335 
such as oedema or DVT which may have multi-factorial contributing factors. 336 
 337 
The NMES device provided a potentially highly significant clinical benefit of helping 338 
to limit the amount of post-operative oedema. The NMES device performed 339 
significantly better than compression stockings in treating post-operative oedema of 340 
the knee and thigh that occurs following THR in both the operated and non-operated 341 
legs. It is acknowledged that the measurement technique for oedema evaluation has 342 
limitations, but given the circumference changes reported, and the steps to ensure 343 
reliability (same assessor and marked points of measurement), it is highly likely the 344 
differences reported are real. Any future studies, most seek to confirm these oedema 345 
findings, and aim to establish the clinical significance of reduced oedema, by linking 346 
to functional outcomes such as muscle function and functional ability.   347 
 348 
In addition, the data provides extremely encouraging data and support for the use of 349 
the gekoTM device which is a new and novel form of NMES. This is because there 350 
were no AEs or SAEs attributable to the NMES device and no device deficiencies 351 
were reported. In addition, all participants were able to tolerate wearing the NMES 352 
devices continuously for the duration of their post-operative recovery in hospital 24 353 
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hours per day. These results suggest that the NMES device is both safe and robust 354 
enough to use in the clinical setting. 355 
 356 
The positive patient tolerability data for the NMES device is especially interesting 357 
given that patient compliance with compression stockings has been previously 358 
reported to be low owing to issues of discomfort, difficulty applying and appearance. 359 
In addition, the use of compression stockings is contra-indicated in patients with leg 360 
oedema, cardiac failure, peripheral vascular insufficiency, and venous ulceration, 361 
which can limit their applicability, particularly in elderly populations who frequently 362 
have hip replacements procedures. Indeed, for patients where 363 
mechanical/pharmacological methods of prophylaxis are impractical or 364 
contraindicated, NICE medical technologies guidance recommend the adoption of 365 
NMES (Summers et al. 2015) and this study further supports the NICE position. 366 
Incorrectly fitted compression stockings have also been associated with ischemia 367 
and increased risk of DVT and a recent study has found a significant increase in skin 368 
problems, including breaks, ulcers, blisters, and necrosis in patients who were fitted 369 
with compression stockings. Future work will need to consider the cost of 370 
compression stockings compared to the NMES device given the current economic 371 
challenges within the National Health Service (NHS). It is acknowledged that 372 
compression stockings may be cheaper to purchase, however health economists 373 
should consider the overall patient cost in regards to readmissions, complications 374 
and additional rehabilitation needs. 375 
 376 
Finally, length of stay (LOS) was not used as an outcome measure within this study 377 
as all participants stayed in hospital for four days due to funding arrangements for 378 
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patient care used within the hospital. However, using NMES to reduce the formation 379 
of post-operative oedema may have a positive effect on LOS. The relationship 380 
between reduced oedema and improvement to muscle strength has not yet been 381 
proven. However we theorise that reducing oedema will encourage mobilisation and 382 
thus improve muscular strength and achievement of discharge criteria and early 383 
functional recovery. 384 
 385 
CONCLUSION 386 
Recent studies on fast-track (or Enhanced Recovery after Surgery) cohorts suggest 387 
that there may be an increased role for non-pharmalogical devices that can be used 388 
whilst walking (Jorgensen & Kehlet 2017). This is the first randomised controlled trial 389 
to evaluate the effectiveness of the gekoTM device. The results of this study suggest 390 
that the NMES device is safe, well tolerated by patients and may be more effective 391 
than compression stockings in reducing the formation of post-operative oedema. In 392 
addition and in respect to DVT prophylaxis, our findings suggest that the NMES 393 
device could be used as adjunctive to chemoprophylaxis or, as recommended by 394 
NICE, as a standalone intervention when other methods are impractical or 395 
contraindicated.  396 
 397 
 398 
 399 
 400 
 401 
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